Stephanie Duehlmeyer
Overview
Explore the profile of Stephanie Duehlmeyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duehlmeyer S, Meier E, Oermann C
Pediatr Pulmonol
. 2024 Oct;
60(1):e27363.
PMID: 39451040
No abstract available.
2.
Tam-Williams J, Oermann C, Duehlmeyer S
Pediatr Pulmonol
. 2024 Aug;
59(12):3774-3776.
PMID: 39150097
No abstract available.
3.
Duehlmeyer S, Elson E, Oermann C
J Pediatr Pharmacol Ther
. 2024 Apr;
29(2):135-139.
PMID: 38596420
Objectives: As cystic fibrosis (CF) lung disease progresses, the airways become infected with opportunistic pathogens, such as (PA). In October 2019, the US Food and Drug Administration approved elexacaftor/tezacaftor/ivacaftor (ETI),...
4.
Elson E, Capel P, Haynes J, Duehlmeyer S, Fischer M, Escobar H
J Pediatr Pharmacol Ther
. 2022 May;
27(4):396-399.
PMID: 35558347
This report describes a case of a 15-year-old male with cystic fibrosis caused by N1303K and Q493X cystic fibrosis transmembrane conductance regulator (CFTR) protein variants. In this case, CFTR modulators...
5.
Duehlmeyer S, Klockau C, Yu D, Rouch J
J Pediatr Pharmacol Ther
. 2021 Jan;
26(1):26-32.
PMID: 33424497
Objectives: To characterize the voriconazole and posaconazole serum trough ordering practices in patients receiving prophylactic and treatment antifungal therapy. Methods: A retrospective chart review over a 6-year period of pediatric...
6.
Rotolo S, Duehlmeyer S, Slack S, Jacobs H, Heckman B
J Cyst Fibros
. 2020 May;
19(5):e39-e41.
PMID: 32471772
Elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the Food and Drug Administration in October 2019 for treatment of cystic fibrosis (CF) in patients 12 years and older with at least one F508del...
7.
Louiselle K, Elson E, Oschman A, Duehlmeyer S
Am J Health Syst Pharm
. 2020 May;
77(14):1097-1099.
PMID: 32435815
No abstract available.
8.
Elson E, Oermann C, Duehlmeyer S, Bledsoe S
Am J Health Syst Pharm
. 2020 May;
77(13):1005-1006.
PMID: 32369111
No abstract available.